Psychedelics and health behaviour change

The paper situates health behaviour change—areas such as diet, physical activity, smoking and alcohol use—within the broader public health imperative to reduce so-called lifestyle diseases and their large personal and economic burdens. It notes that despite decades of public health efforts many unhealthy behaviours remain prevalent, and argues that novel adjunctive approaches deserve exploration. The authors introduce classic psychedelics (for example psilocybin, LSD, and DMT/ayahuasca) as compounds with a long ethnographic history and a modern resurgence of clinical research, including promising early results for mood disorders, cancer-related distress and substance use disorders. Teixeira and colleagues set out to explore links between psychedelic pharmacology, psychological mechanisms, and evidence of spontaneous or trial-related changes in lifestyle behaviours. Their aim is not to present a new randomised trial but to synthesise neurobiological, psychological and preliminary clinical/observational evidence to generate hypotheses about how psychedelic-assisted interventions might support sustained health behaviour change and to propose conceptual frameworks that could guide future research and therapeutic models.

The extracted text does not report a formal methods section describing a systematic search strategy, inclusion criteria, or meta-analytic procedures. Instead, the paper appears to be a narrative, integrative review that draws on historical clinical trials from the mid-20th century, contemporary clinical trials and follow-ups, observational surveys, qualitative studies, and theoretical models from neuroscience and psychology. Evidence sources described in the text include: early LSD research and its meta-analyses from the 1950s–70s; recent clinical trials of psilocybin for depression, cancer-related distress and substance use disorders (including smoking cessation); observational studies of ayahuasca users; survey studies of people reporting reductions in alcohol or other drug use after psychedelic experiences; qualitative analyses of treatment participants (including those with eating disorders); and a study of self-reported effects of microdosing. The authors also integrate neuroscientific findings (receptor pharmacology, network-level brain changes, synaptogenesis) and behavioural theories such as self-determination theory and Acceptance and Commitment Therapy to build mechanistic hypotheses.

Neuroscientific and mechanistic findings: The review summarises evidence that classic psychedelics act primarily as agonists at the serotonin 5-HT2A receptor, with downstream effects including increased neuronal excitability of layer V pyramidal neurons, higher signal complexity or entropy of field potentials, disruption of large-scale intrinsic networks (for example the default-mode network), increased inter-network communication, and promotion of cortical synaptogenesis. The authors describe the REBUS (relaxed beliefs under psychedelics) model, which proposes that psychedelics reduce the precision-weighting of high-level priors in hierarchical predictive processing, thereby creating a window for cognitive and behavioural flexibility. Psychological and personality-level effects: Evidence presented indicates psychedelics can produce acute increases in cognitive flexibility, shifts in perspectives about the self and relationships, transient increases in openness to experience, and enhanced creative thinking in appropriate contexts. The paper proposes that these changes may translate into exploratory behaviour consistent with newly acquired values or beliefs—for example choosing different environments for exercise or altering dietary preferences. Self-determination framework: The authors map reported psychedelic effects onto self-determination theory constructs—autonomy, competence and relatedness—and report trial participant accounts suggestive of increases in these domains. Examples from qualitative analyses include self-reported increases in confidence, commitment to change, insight into self-identity, and enhanced feelings of connectedness; the text suggests these changes could support autonomous motivation for sustained behaviour change, though direct empirical tests are not yet available. Observational and survey evidence of spontaneous behaviour change: Several cross-sectional and survey studies are summarised. In an observational sample of 380 ayahuasca users, mean BMI was reported as 22.6 kg/m2 compared with an estimated general-population figure of around 26 kg/m2 in Spain (2016), and high proportions reported daily fruit and vegetable intake (3–6 servings). In a US survey of 343 people who claimed reduced alcohol misuse after a psychedelic experience, 63% endorsed improved diet and 55% increased exercise. A similar survey of 444 participants reporting reductions in cannabis, opioid, or stimulant misuse found 59% reported improved diet and 58% increased exercise. A microdosing study of 278 self-selected users reported spontaneous improvements in meditative practice (49.1%), exercise (49.1%), eating habits (36.0%), and sleep (28.8%), and reductions in caffeine (44.2%), alcohol (42.3%) and tobacco (21.0%). The authors note these studies are limited by cross-sectional designs, convenience samples, self-report, and lack of control groups. Clinical trial and addiction-related findings: The review recounts historical meta-analytic evidence from 6 double-blind LSD studies indicating short- and medium-term benefits for alcohol abstinence but no effect at 12 months. Recent psilocybin-assisted interventions for alcohol dependence and tobacco smoking have shown encouraging outcomes: after 2–3 drug sessions combined with behavioural therapy, biologically verified smoking abstinence at 12 months and at about 30 months substantially exceeded success rates of standard treatments reported in the literature. Qualitative analyses from smoking cessation trials attribute therapeutic mechanisms to improved mood, shifts in life priorities and values, motivational insights and emotional regulation. Johns Hopkins studies reported 51% increases in a self-rated "positive behavior changes" scale from baseline to end of treatment in smoking cessation trials; psilocybin trials in cancer-related distress reported similar increases in positive behaviours and long-term gains, with a 4.5-year follow-up indicating 86% of a small sample reported sustained improvements in well-being and 100% reported positive behaviour changes (sample sizes n=12–14 in those follow-ups). A qualitative study of 16 people with eating disorders who had taken part in ayahuasca ceremonies reported reductions in disorder-related negative thoughts, improved emotion regulation and reports of symptom remission or improved symptom management, although no specific behavioural measures were recorded. Therapeutic models and adjunctive approaches: The authors describe therapeutic frameworks that have been used or proposed to support psychedelic interventions aimed at behaviour change. The ACE model (Accept, Connect, Embody), derived from Acceptance and Commitment Therapy (ACT), was used in psilocybin treatment for depression. The review also highlights Cognitive Behavioral Therapy and Motivational Interviewing (or Motivational Enhancement Therapy) as established behaviour-change approaches compatible with psychedelic-assisted interventions and consistent with self-determination theory principles.

Teixeira and colleagues interpret the amassed evidence as suggestive but preliminary: psychedelics appear to induce neurobiological and psychological states—reduced rigidity of high-level beliefs, increased plasticity and exploratory behaviour, and enhanced openness—that plausibly create opportunities for sustained lifestyle change when combined with appropriate therapeutic support. They propose self-determination theory as a useful conceptual framework linking psychedelic experiences to autonomous motivation for healthful behaviour change, and note observational and clinical data that people often report spontaneous improvements in diet, exercise, connectedness and other pro-health behaviours after psychedelic experiences. The authors acknowledge several important limitations in the evidence base. Much of the literature they review is small-sample, open-label, qualitative or cross-sectional, often relying on self-selected convenience samples and self-report measures. Where stronger designs exist—such as recent psilocybin-assisted smoking cessation trials—sample sizes remain modest and replication is needed. The paper emphasises the lack of studies specifically designed to target behaviours such as diet or physical activity with psychedelic-assisted interventions, and notes that microdosing findings may not generalise to high-dose therapeutic models. In terms of clinical and research implications the authors argue for cautious, hypothesis-driven development: future trials should explicitly target health behaviours, compare psychotherapeutic models (for example ACT/ACE, CBT, Motivational Interviewing), and prospectively measure relevant behavioural outcomes. They also discuss societal concerns—such as fears that psychedelics might encourage disengagement from mainstream responsibilities—and report that available clinical-observer data do not support such negative outcomes, instead showing improved functioning in community-rated assessments. Finally, the authors stress the importance of professional boundaries and the avoidance of countercultural or supernatural framing in clinical settings as psychedelic therapies move toward wider therapeutic use, and suggest that if psychedelics act on general processes like relaxed beliefs and psychological flexibility, they could become transdiagnostic enhancers of behaviour change across disorders and lifestyle challenges.